

---

## Press Release

---

June 26, 2025

Sumitomo Pharma Co., Ltd.

### **Sumitomo Pharma Announces Organizational Realignment**

Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Toru Kimura) announced today that the Company has implemented the following organizational realignment, effective June 26, 2025.

#### **Organizational Realignment (effective June 26, 2025)**

Secretariat, Audit & Supervisory Board is renamed to Audit and Supervisory Committee Office.

\*At the 205th Ordinary General Shareholders' Meeting held today (June 26, 2025), the transition to an "Audit & Supervisory Committee" was approved. Accordingly, Secretariat, Audit & Supervisory Board is renamed to Audit and Supervisory Committee Office.

Contact:

Corporate Communications, Corporate Governance

Sumitomo Pharma Co., Ltd.

E-mail: [prir@sumitomo-pharma.co.jp](mailto:prir@sumitomo-pharma.co.jp)